FDA Brief

Warning letters Devices

FDA warning letter to

BlephEx, LLC

High riskIssued Jun 3Posted Jul 7Center for Devices and Radiological Health

FDA says BlephEx sold three eye devices without required FDA clearance and missed device reports.

What happened

FDA inspected BlephEx in Brentwood, TN from October 30 to November 19, 2025, reviewed the company website, and considered responses through May 29, 2026. FDA found the BlephEx eyelid cleaning sponge and two OptiVize eye devices marketed for uses beyond their legally marketed device types without required premarket approval or 510(k) clearance. The inspection also found no correction/removal report for handpieces or chargers that smoked or blew up, missing UDI data in FDA’s GUDID database, and inadequate handling of 177+ complaints.

What FDA found

  1. FDA says the BlephEx eyelid cleaning sponge was marketed for blepharitis, dry eye, pre-cataract and pre-LASIK uses without an approved PMA or 510(k), so it is adulterated and misbranded.

    FD&C Act §§ 501(f)(1)(B), 502(o); 21 U.S.C. §§ 351(f)(1)(B), 352(o); 21 CFR 807.81(a)
  2. FDA says the OptiVize electrolysis unit was marketed for biofilm removal and with a harmonic waveform/eyelid plate, uses different from the exempt ophthalmic electrolysis unit, without a 510(k).

    FD&C Act §§ 501(f)(1)(B), 502(o); 21 U.S.C. §§ 351(f)(1)(B), 352(o); 21 CFR 886.9(a), 886.9(b), 807.81(a)
  3. FDA says the OptiVize forceps was marketed to clear meibomian glands using heat and vibration, a different use from an exempt manual ophthalmic surgical instrument, without a 510(k).

    FD&C Act §§ 501(f)(1)(B), 502(o); 21 U.S.C. §§ 351(f)(1)(B), 352(o); 21 CFR 886.9(a), 807.81(a)
  4. BlephEx did not submit a correction/removal report within 10 working days after sending replacement chargers because handpieces or Type G chargers had smoked or blown up.

    21 CFR 806.10; FD&C Act § 502(t)(2), 21 U.S.C. § 352(t)(2)
  5. BlephEx did not submit required unique device identifier information for the three devices to FDA’s GUDID database.

    21 CFR 801.20(a); 21 CFR 830.300(a); 21 CFR 830.320(b); FD&C Act § 502(t)(2), 21 U.S.C. § 352(t)(2)
  6. BlephEx’s complaint procedure and records did not ensure 177+ complaints were uniformly reviewed, investigated when needed, or evaluated for medical device reporting.

    21 CFR 820.198(a)-(d); 21 CFR Part 803

What FDA wants

FDA asks BlephEx to stop activities that make the three devices misbranded or adulterated, including commercial distribution for the cited uses. The provided letter excerpt does not state a response deadline.

Who should pay attention

  • eye-care clinics and surgeons using BlephEx or OptiVize devices
  • distributors and brands selling or relabeling these devices
  • medical device quality teams handling complaints, MDRs and UDI reporting

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  2. Peter Schiff Enterprises

    FDA warns Peter Schiff Enterprises over unapproved cardiac devices and serious quality system failures.

    High risk
  3. Pro-Optics, LLC

    FDA warned Pro-Optics about unapproved material and color changes to contact lens cases and quality system failures.

    Medium
  4. Tides Medical LLC

    FDA warns Tides Medical over APLICOR 3D wound device sold without approval, exemption, or required FDA notice.

    High risk